13F reference period
Q3 2026
Security Snapshot
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) Institutional Ownership
CUSIP: 45720N103
13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026
Institutions Reporting
84
Shares (Excl. Options)
6.12M
Full value: 6,122,103 · shares · 30 Sep 2026Price
$100.08
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- INBX on Nasdaq
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 6,122,103
- Total 13F value
- $612,516,608
- Portfolio coverage rank
- 0%
- Share change
- -168,001
- Value change
- -$15,256,254
- Number of holders
- 84
- Shares outstanding
- 14,728,887
- SEC-reported price per share
- $92.76
- Insider filing price
- $92.76
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45720N103.
- 84 institutions reported positions in Q3 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 161 to 84 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$1.36B
Full value: $1,357,616,333 · USD · 30 Jun 2026.$612.52M
Full value: $612,516,608 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 84 institutions filings for Q3 2026.
Security key
45720N103
13F reference period
Q3 2026
13F holders
84
13D/G owners
8
CIK / CUSIP context first
Open Q3 2026 holders
INBX full holder history
Inhibrx Biosciences, Inc. SEC filings
Inhibrx Biosciences, Inc. company facts
Inhibrx Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45720N103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
INBX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% | 0% | $144,624,915 | +$2,751,620 | 1,489,443 | +1.9% | Perceptive Advisors LLC | 30 Jun 2026 |
| VIKING GLOBAL INVESTORS LP | 9.3% | -6.9% | $134,349,599 | -$7,574,965 | 1,383,621 | -5.3% | VIKING GLOBAL INVESTORS LP | 30 Jun 2026 |
| MORGAN STANLEY | 7.9% | $84,668,884 | 1,155,416 | Morgan Stanley | 31 Dec 2025 | |||
| Kayyem Jon Faiz | 7.9% | $13,765,571 | 1,149,046 | Jon Faiz Kayyem | 03 Jun 2024 | |||
| Schonfeld Strategic Advisors LLC | 6.5% | +23% | $88,396,477 | +$15,888,026 | 952,959 | +22% | Schonfeld Strategic Advisors LLC | 30 Sep 2026 |
| Lappe Mark | 6.4% | $11,086,448 | 925,413 | Mark Lappe | 12 Sep 2024 | |||
| BlackRock, Inc. | 5.3% | +12% | $60,682,270 | +$6,933,198 | 768,130 | +13% | BlackRock, Inc. | 31 Dec 2025 |
| BANK OF AMERICA CORP /DE/ | 2.4% | -58% | $35,760,350 | -$50,039,950 | 357,318 | -58% | BANK OF AMERICA CORP /DE/ | 30 Sep 2026 |
As of 30 Sep 2026,
84
institutional investors reported holding
shares of
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX).
This represents
42%
of the company’s total
outstanding shares.
6.12M
Full value: 6,122,103 · shares · 30 Sep 202614.73M
Full value: 14,728,887 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | 9% | 1,320,661 | +0.96% | 0.01% | $132,171,793 |
| Sanofi | 7.9% | 1,157,926 | 0% | 18% | $115,885,234 |
| HighTower Advisors, LLC | 6% | 884,441 | +1.6% | 0.08% | $88,514,822 |
| STATE STREET CORP | 3.8% | 565,749 | -12% | 0% | $56,620,160 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 537,262 | +9.1% | 0% | $53,769,181 |
| Capital Research Global Investors | 2.5% | 362,466 | -0.16% | 0.01% | $36,275,597 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 255,317 | -0.33% | 0% | $25,558,180 |
| CDC Financial, Inc. | 0.9% | 132,290 | -5.6% | 12% | $13,239,583 |
| FIRST TRUST ADVISORS LP | 0.86% | 126,651 | -1.4% | 0.01% | $12,675,232 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | 0.81% | 119,200 | 0% | 0.05% | $11,929,536 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.76% | 112,157 | -8.5% | 0% | $11,224,673 |
| Invesco Ltd. | 0.63% | 92,518 | +449% | 0% | $9,259,201 |
| VANGUARD FIDUCIARY TRUST CO | 0.48% | 71,026 | +1.6% | 0% | $7,108,282 |
| BNP PARIBAS FINANCIAL MARKETS | 0.39% | 58,098 | 0% | $5,814,448 | |
| Hudson Bay Capital Management LP | 0.17% | 25,001 | 0.01% | $2,502,100 | |
| Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | 0.15% | 22,584 | 0% | 0.03% | $2,260,207 |
| Quantinno Capital Management LP | 0.12% | 17,353 | -0.25% | 0% | $1,736,688 |
| FRANKLIN TEMPLETON INC | 0.1% | 15,178 | +14% | 0% | $1,316,843 |
| MARSHALL WACE, LLP | 0.1% | 14,953 | +70% | 0% | $1,496,496 |
| TEMA ETFS LLC | 0.1% | 14,407 | +42% | 0.05% | $1,441,853 |
| Tidal Investments LLC | 0.1% | 14,407 | +42% | 0% | $1,441,853 |
| Swiss National Bank | 0.1% | 14,100 | +1.4% | 0% | $1,411,128 |
| Rafferty Asset Management, LLC | 0.1% | 14,099 | +26% | 0% | $1,411,028 |
| Mariner, LLC | 0.07% | 10,925 | +139% | 0% | $1,093,374 |
| Ethic Inc. | 0.06% | 9,259 | -0.92% | 0.01% | $926,641 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Headline period
Q3 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 6,122,103 | $612,516,608 | -$15,256,254 | $100.08 | 84 |
| 2026 Q2 | 14,331,102 | $1,357,616,333 | +$160,622,454 | $94.75 | 161 |
| 2026 Q1 | 12,713,962 | $854,579,371 | -$23,515,793 | $67.23 | 134 |
| 2025 Q4 | 12,777,957 | $1,009,450,205 | +$184,334,509 | $79.00 | 139 |
| 2025 Q3 | 10,497,334 | $353,550,847 | +$6,764,063 | $33.68 | 101 |
| 2025 Q2 | 10,435,616 | $148,917,132 | -$5,468,523 | $14.27 | 87 |
| 2025 Q1 | 10,790,279 | $150,950,613 | -$5,227,676 | $13.99 | 92 |
| 2024 Q4 | 11,165,626 | $171,927,470 | +$10,221,839 | $15.40 | 101 |
| 2024 Q3 | 8,897,409 | $139,328,871 | -$10,813,194 | $15.66 | 95 |
| 2024 Q2 | 9,650,613 | $136,747,433 | +$136,582,849 | $14.17 | 86 |